Please see the LUCADA data manual v3.1.3, available in the downloads section
|
|
|
- Ambrose Small
- 10 years ago
- Views:
Transcription
1 National Lung Cancer Audit Frequently Asked Questions What dataset should be used? Please see the LUCADA data manual v3.1.3, available in the downloads section What does LUCADA stand for? LUCADA stands for Lung Cancer Data Who has agreed the outputs and supporting dataset? The NLCA Clinical Reference Group (CRG) identified the priority outputs of the audit. What software is to be used for collecting the LUCADA dataset? The programme has commissioned the development of a web-based (NHSnet) audit IT infrastructure system from the National Health Applications & Infrastructure Services (NHS CFH). What are the security arrangements for LUCADA? Each organisation must first complete a data user certificate, this identifies all users of the system and requires the signature of the Trust Caldicott Guardian. Access to the system is controlled by centrally assigned user names and passwords. The core system uses the same access and security controls as the Open Exeter and CWT systems; named access is over a secure network through the Open Exeter portal Is it possible to upload data to the central database, rather than via the data entry screens? Yes, both CSV and XML file specifications are being developed for upload to the central database.
2 When can an organisation start to use the audit application? As soon as the registration has been processed and a password issued. How long is a password valid for? Passwords expire every 28 days and hence must be changed every 28 days. If a password is not reset within the 28 day window, a call must be logged with the helpdesk who will reset it. If a password it not used for 6 months, the user account expires and a new account must be applied for using the clinical audit form. At what point should the Performance Status be recorded? The Performance Status should be recorded at the point in time closest to the start of treatment. It should be updated if it differs from the original Performance Status entered. Is there a proforma I can use to help me collect the audit data? A proforma is available in the downloads section. As well as the full audit dataset it also highlights the key fields that are essential for the audit. What data should be entered into data field 5.5 (Cancer Care Plan Intent)? There has been uncertainty around the correct interpretation of this field. This is partly due to conflicting data definitions between LUCADA and Cancer Waiting Times and partly due to differences in data definitions between lung cancer and mesothelioma. Data Field 5.5 CANCER CARE PLAN INTENT should be used to record the intention of the treatment which is planned for the patient at this point in time.
3 Intent Plan Details Curative (C) Surgical resection (including open and close' but excluding all surgery on mesothelioma patients) Radical radiotherapy to primary site with potential for cure Chemotherapy in Limited Stage and/or Good Prognosis Small Cell Carcinoma (e.g. using Manchester' prognostic score) Adjuvant (or neo-adjuvant) chemotherapy (combined with surgery) in Non-Small Cell Carcinoma Adjuvant radiotherapy in Small Cell carcinoma Prophylactic Cranial Irradiation Palliative (P) Specialist Palliative Care Chemotherapy in Non-Small Cell Carcinoma (excepting Adjuvant and Neo-adjuvant therapy) Radiotherapy to primary tumour with palliative intent Radiotherapy to site of secondary cancer Brachytherapy (Endobronchial radiotherapy) Other endobronchial treatments (e.g. laser therapy, diathermy, cryotherapy, insertion of bronchial stent) Chemotherapy in Extensive Stage and/or Poor Prognosis Small Cell Carcinoma (e.g. using the Manchester' prognostic score) Surgery for mesothelioma (EPP, debulking surgery and pleurodesis) Surgical Pleurodesis Superior Vena Caval Stenting Palliative - supportive care only (S) This item implies follow up with the aim of identifying symptoms and treating these if and when appropriate. Follow up could be through primary care, secondary care and includes doctors, nurses and Macmillan staff. The plan implies that no immediate treatment is to be given but does not exclude the patient from having treatment at a future date if the need arose. No specific anti-cancer treatment (N) Unknown (9) It is highly unlikely that any treatment plan would be drawn up, where the intention of the treatment is Unknown. The use of this code should be carefully monitored. Important messages: All surgery in mesothelioma patients is to be classified as palliative (P) Pleurodesis, whether medical or surgical, is to be classified as palliative (P)
4 EXAMPLES: 5.5 Scenario C Patient has clinical or histological diagnosis of lung cancer undergoes surgery with curative intent. P Patient has clinical or histological diagnosis of mesothelioma - undergoes EPP, debulking or surgical pleurodesis. P Patient has clinical or histological diagnosis of lung cancer - undergoes surgical or medical pleurodesis. C Patient has clinical or histological diagnosis of lung cancer - undergoes potentially curative chemotherapy and also has surgical or medical pleurodesis. In the latter example, the pleurodesis is recorded as a palliative care intervention in sections L41/L42. What data should be entered into data field L29 (Treatment Planned)? There has been uncertainty around the correct interpretation of these fields. This is partly due to conflicting data definitions between LUCADA and Cancer Waiting Times and partly due to differences in data definitions between lung cancer and mesothelioma. Data Field L29 (TREATMENT PLANNED) should be used to record the type of treatment regimen planned. Code Treatment 01 Surgery For Lung Cancer patients (including clinical diagnoses) - record here any surgical procedure under taken with the intention of curing the patient.do not record here any procedures undertaken for purely diagnostic purposes these should beentered in the Care Plan / MDT section. For Mesothelioma patients - it is accepted that all surgical procedures in this group of patients are palliative. Please enter any therapeutic procedures as surgery other (E57.8). Do not record here any procedures undertaken for purely diagnostic purposes these should be entered in the Care Plan / MDT section. 02 Teletherapy / Radiotherapy
5 03 Chemotherapy 04 Brachytherapy 05 Palliative care 06 Active Monitoring 07 Sequential chemotherapy and radiotherapy 08 Concurrent chemotherapy and radiotherapy 09 Induction chemotherapy to downstage before surgery 10 Neo-adjuvant chemotherapy and surgery 11 Surgery followed by adjuvant chemotherapy EXAMPLES: L29 Scenario 01 Patient has clinical or histological diagnosis of lung cancer undergoes surgery with curative intent. 01 Patient has clinical or histological diagnosis of mesothelioma - undergoes EPP, debulking or surgical pleurodesis. 05 Patient has clinical or histological diagnosis of lung cancer - undergoes surgical or medical pleurodesis. 03 Patient has clinical or histological diagnosis of lung cancer - undergoes potentially curative chemotherapy and also has surgical or medical pleurodesis. In the latter example, the pleurodesis is recorded as a palliative care intervention in sections L41/L42.
The National Clinical Lung Cancer Audit (LUCADA)
The National Clinical Lung Cancer Audit (LUCADA) DATA MANUAL Title: Version: 3.1.5 Date: September 2013 LUCADA Lung Cancer Audit VERSION HISTORY Version Date Issued Brief Summary of Change Owner s Name
Treatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians
Treatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians Background The Cancer Institute New South Wales Oncology Group Lung (NSWOG Lung) identified the need for the development
Key findings about the quality of care for people with Lung Cancer in England incorporating headline and completeness data from Wales
National Lung Cancer Audit Key findings about the quality of care for people with Lung Cancer in England incorporating headline and completeness data from Wales Report for the audit period 2005 Prepared
2015/16 NHS STANDARD CONTRACT FOR ACUTE, AMBULANCE, COMMUNITY AND MENTAL HEALTH AND LEARNING DISABILITY SERVICES (MULTILATERAL)-
2015/16 NHS STANDARD CONTRACT FOR ACUTE, AMBULANCE, COMMUNITY AND MENTAL HEALTH AND LEARNING DISABILITY SERVICES (MULTILATERAL)- SECTION B PART 1 - SERVICE SPECIFICATION FOR LUNG CANCER Service specification
National Lung Cancer Audit Report
National Lung Cancer Audit Report 2013 Report for the audit period 2012 Copyright 2013, Health and Social Care Information Centre, National Lung Cancer Audit. All rights reserved. 1 Prepared in partnership
Radiation Therapy in the Treatment of
Lung Cancer Radiation Therapy in the Treatment of Lung Cancer JMAJ 46(12): 537 541, 2003 Kazushige HAYAKAWA Professor and Chairman, Department of Radiology, Kitasato University School of Medicine Abstract:
How treatment is planned Giving your consent The benefits and disadvantages of treatment Second opinion
Treatment overview for lung cancer This information is an extract from the booklet Understanding lung cancer. You may find the full booklet helpful. We can send you a free copy see page 5. Contents How
SMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
Salisbury Lung Cancer Service (1 of 5)
Salisbury Lung Cancer Service (1 of 5) i If you need this information in another language or medium (audio, large print, etc) please contact Customer Care on 0800 374 208 email: customercare@ salisbury.nhs.uk.
How To Treat Mesothelioma
Mesothelioma in the UK Liz Darlison Mesothelioma UK The National Macmillan Mesothelioma Resource Centre June 2010 Mesothelioma Applied Research Foundation - 2010 www.curemeso.org Contents Size of Mesothelioma
How To Prepare A Meeting For A Health Care Conference
THORACIC ONCOLOGY MULTIDISCIPLINARY TEAM MEETINGS: OPERATIONAL POLICY EXECUTIVE SUMMARY 1. All patients in Lothian with thoracic malignancies should be discussed at designated times in pathway (see App
Surgery. Wedge resection only part of the lung, not. not a lobe, is removed. Cancer Council NSW
The treatment you receive will depend on your lung cancer type, for example, whether you have a non-small cell lung cancer Adenocarcinoma or Squamous cell carcinoma, and if this is a sub-type with a mutation.
7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
National Bowel Cancer Audit Report 2008 Public and Executive Summary
National Bowel Cancer Audit Report 2008 Public and Executive Summary Prepared in association with: Healthcare Quality Improvement Partnership HQIP Association of Coloproctology of Great Britain and Ireland
PRIMARY LUNG CANCER TREATMENT
PRIMARY LUNG CANCER TREATMENT Cancer Care Pathways Directorate Tailored Information in Cancer Care (TICC) Sir Anthony Mamo Oncology Centre December 2014 Contents About this booklet 1 Types of Lung Cancer
How To Treat A Cancer With A Radical
Management of mesothelioma [email protected] Amsterdam, March 6, 2010 1 management Palliation Symptomatic care Pain Breathlessness Radiotherapy Chemotherapy Surgery Radical (intention to cure)
Cancer research in the Midland Region the prostate and bowel cancer projects
Cancer research in the Midland Region the prostate and bowel cancer projects Ross Lawrenson Waikato Clinical School University of Auckland MoH/HRC Cancer Research agenda Lung cancer Palliative care Prostate
Lung Cancer & Mesothelioma 2011-2015
Lung Cancer & Mesothelioma 2011-2015 Annex G Mesothelioma 1. The vision for mesothelioma services is set out in the Mesothelioma Framework issued by DH on 26 February 2007 (supported by the British Thoracic
CANCER WAITING TARGETS A GUIDE (VERSION 5)
National Cancer Waits Project CANCER WAITING TARGETS A GUIDE (VERSION 5) Cancer Action Team Amendments from version 4 to version 5 The waiting times guide has been updated from version 4. Sections which
AA Life Insurance providing access to Best Doctors. AA Life Insurance is provided by Friends Life and Pensions Limited
AA Life Insurance is provided by Friends Life and Pensions Limited What would be the first thing you might think about if you were diagnosed with a serious illness? 2 It is very likely that the first thing
POLICY A. INDICATIONS
Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below
Lung Cancer Treatment Guidelines
Updated June 2014 Derived and updated by consensus of members of the Providence Thoracic Oncology Program with the aid of evidence-based National Comprehensive Cancer Network (NCCN) national guidelines,
Radiotherapy in locally advanced & metastatic NSC lung cancer
Radiotherapy in locally advanced & metastatic NSC lung cancer Dr Raj Hegde. MD. FRANZCR Consultant Radiation Oncologist. William Buckland Radiotherapy Centre. Latrobe Regional Hospital. Locally advanced
IAPT Data Standard. Frequently Asked Questions
IAPT Data Standard Frequently Asked Questions Version 1.0 March 2012 IAPT FAQs 1.0-1 - Contents Section 1: About the IAPT Data Standard.. 3 Section 2: Who is responsible for doing what?. 5 Section 3: How
Lung Cancer in the West Midlands
West Midlands Cancer Intelligence Unit Lung Cancer in the West Midlands Supporting the fight against cancer through timely, high quality information provision R11/05 November 2011 0 Author: TE Last updated:
Clinical Commissioning Policy: Proton Beam Radiotherapy (High Energy) for Paediatric Cancer Treatment
Clinical Commissioning Policy: Proton Beam Radiotherapy (High Energy) for Paediatric Cancer Treatment Reference: NHS England xxx/x/x 1 Clinical Commissioning Policy: Proton Beam Radiotherapy (High Energy)
This factsheet aims to outline the characteristics of some rare lung cancers, and highlight where each type of lung cancer may be different.
There are several different kinds of lung cancer, often referred to as lung cancer subtypes. Some of these occur more often than others. In this factsheet we will specifically look at the subtypes of cancers
The Role of the MDT Coordinator. Laura Throssell
The Role of the MDT Coordinator Laura Throssell NHS Cancer Plan (2000) the care of all patients with cancer should be formally reviewed by a specialist team. all patients have the benefit of the range
AA Life Insurance providing access to Best Doctors. AA Life Insurance is provided by Friends Life Limited
AA Life Insurance is provided by Friends Life Limited What would be the first thing you might think about if you were diagnosed with a serious illness? It is very likely that the first thing you might
Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof.
Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Alberto Riccardi SMALL CELL LUNG CARCINOMA Summary of treatment approach * limited
1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1
1 page Overview 21 Oct Tuesday 1500 on REGISTRATION 1800 Welcome Reception & Cocktails at the Cape Town International Conference Centre (CTICC) 22 Oct Wednesday 0730 REGISTRATION 0830 OPENING 0900 PLENARY
How To Contact The Lung Cancer And Mesothelioma Multi-Disciplinary Team
Oxford University Hospitals NHS Trust Oxford Lung Cancer and Mesothelioma Multi- Disciplinary Team (MDT) This information leaflet explains the role of the Multi-Disciplinary Team and Specialist Nursing
Management of Non-Small Cell Lung Cancer Guide for General Practitioners
Management of n-small Cell Lung Cancer Guide for General Practitioners Clinical Stage I Cancer only in one lobe of lung and
Probe: Could you tell me about when?
PERIODIC ASSESSMENT OF TREATMENT AND VITAL/DISEASE STATUS Periodic Assessment of Cancer Treatment and Disease Status (To be administered to patient at 3 months and reviewed at 6, 9 and 12 months) Instructions:
Report series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
a commitment in their practice to the roles and responsibilities of clinical oncologists X
CLINICAL ONCOLOGY BLUEPRINT OF ASSESSMENT SYSTEM Good Medical Practice areas of curriculum - ST5 (Intermediate) Standards GMP criterion Workplace based assessment By the end of the third year of training
Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines
Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines Wieneke Buikhuisen The Netherlands Cancer Institute Amsterdam The Netherlands Case (1) Male, 56 year
Surgical therapy of. who should be operated
SAMO Interdisciplinary Workshop on Chest Tumors Lucerne, 13th and 14th January 2012 Surgical therapy of mesothelioma, who should be operated Walter Weder MD Professor of Surgery University Hospital Zurich
Lung Cancer in 2015: A Multidisciplinary Update
Lung Cancer in 2015: A Multidisciplinary Update Invited Guest Faculty: Toronto General Hospital Toronto, Canada Saturday April 18, 2015 7:00 am-4:30 pm Westin Pasadena 191 N. Los Robles Avenue Pasadena,
Lung cancer case study
Change Presentation title and date in Footer dd.mm.yyyy Lung cancer case study Dr Jaishree Bhosle Consultant Medical Oncologist Change Presentation title and date in Footer dd.mm.yyyy 1 2 Part One Initial
Small Cell Lung Cancer
Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually
The following information is only meant for people who have been diagnosed with advanced non-small cell
Important information for people with advanced non-small cell lung cancer The following information is only meant for people who have been diagnosed with advanced non-small cell lung cancer (NSCLC). NSCLC
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); [email protected] Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
Stage I, II Non Small Cell Lung Cancer
Stage I, II Non Small Cell Lung Cancer Best Results T1 (less 3 cm) N0 80% 5 year survival No Role Adjuvant Chemotherapy Radiation Therapy Reduces Local Recurrence No Improvement in Survival 1 Staging Mediastinal
Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines
Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines April 2008 (presented at 6/12/08 cancer committee meeting) By Shelly Smits, RHIT, CCS, CTR Conclusions by Dr. Ian Thompson, MD Dr. James
Access to over 53,000 of the world s leading medical experts, from your first day of cover.
For customers Friends Life Individual Protection providing access to Best Doctors Access to over 53,000 of the world s leading medical experts, from your first day of cover. A second medical opinion could
Small cell lung cancer
Small cell lung cancer Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. The lungs are a pair of cone-shaped breathing organs that are found within
Tubular breast cancer
Tubular breast cancer This booklet is for people who would like more information about tubular breast cancer. It describes what tubular breast cancer is, its symptoms, how a diagnosis is made and the possible
REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group
REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory
Breast cancer research and a changing treatment pathway
Breast cancer research and a changing treatment pathway Stuart McIntosh Clinical Senior Lecturer in Surgical Oncology, QUB Consultant Breast Surgeon, BCH What is the breast surgeon s role in 2016? Surgery
Breast Cancer Care & Research
Breast Cancer Care & Research Professor John FR Robertson University of Nottingham Nottingham City Hospital Breast Cancer (BC) 15,000 BC deaths in the UK each year 20% female cancer deaths 5% all female
Breast Cancer. Presentation by Dr Mafunga
Breast Cancer Presentation by Dr Mafunga Breast cancer in the UK Breast cancer is the second most common cancer in women. Around 1 in 9 women will develop breast cancer It most commonly affects women over
International Symposium on Malignant Pleural Mesothelioma
International Symposium on Malignant Pleural Mesothelioma LONDON 2015 Friday 6th & Saturday 7th November 2015 Jumeirah Carlton Tower Hotel Cadogan Place Knightsbridge London SW1X 9PY United Kingdom Dear
Measuring quality along care pathways
Measuring quality along care pathways Sarah Jonas, Clinical Fellow, The King s Fund Veena Raleigh, Senior Fellow, The King s Fund Catherine Foot, Senior Fellow, The King s Fund James Mountford, Director
Clinical Management Guideline Management of locally advanced or recurrent Renal cell carcinoma. Protocol for Planning and Treatment
Protocol for Planning and Treatment The process to be followed in the management of: LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA Patient information given at each stage following agreed information
Information for Men Diagnosed with Testicular Cancer
Patient Information Service Information for Men Diagnosed with Testicular Cancer Bristol Haematology and Oncology Centre Bristol Testicular Cancer Service Patient Information is supported by September
Guide to Private Medical Insurance
Guide to Private Medical Insurance Contents About the Exeter 4 Why private medical insurance? 5 Product highlights 6 Cover and benefits 10 Getting the right premium 15 How to apply 16 Claims overview 21
The role of the Specialist Nurse Practitioner for Late Effects Information for patients
Oxford University Hospitals NHS Trust The role of the Specialist Nurse Practitioner for Late Effects Information for patients This leaflet describes the role of the Specialist Nurse Practitioner for Late
Guidelines for Management of Renal Cancer
Guidelines for Management of Renal Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Changes Between Versions 2 and 3 Section 5 updated bullets 5.3 and 5.4 Section 6 updated
YCN Lung NSSG YCN Radiotherapy & Chemotherapy Guidelines for Lung Cancer & Mesothelioma
YCN Lung NSSG YCN Radiotherapy & Chemotherapy Guidelines for Lung Cancer & Mesothelioma *** VALID ON DATE OF PRINTING ONLY - all guidelines available at http://www.ycn.nhs.uk/ *** page 1 of 83 i Document
UnitedHealthcare Injectable Chemotherapy Prior Authorization (PA) Program Frequently Asked Questions
UnitedHealthcare Injectable Chemotherapy Prior Authorization (PA) Program Frequently Asked Questions Q1. What members are impacted by the UnitedHealthcare Injectable Chemotherapy PA Program? A. Beginning
Understanding your pathology report
Understanding your pathology report 2 Contents Contents Introduction 3 What is a pathology report? 3 Waiting for your results 4 What s in a pathology report? 4 Information about your breast cancer 5 What
Table of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms
Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation
4.8 Lung cancer. 4.8.5 In the UK, three fractionation regimens are most commonly used:
4.8 Lung cancer 4.8.1 In 2005, both NICE (National Institute for Health and Clinical Excellence) and SIGN (Scottish Intercollegiate Guidelines Network) published guidelines on the management of lung cancer.
OVARIAN CANCER TREATMENT
OVARIAN CANCER TREATMENT Cancer Care Pathways Directorate Tailored Information in Cancer Care (TICC) Sir Anthony Mamo Oncology Centre National Cancer Plan May 2015 Contents About this booklet 1 The Ovaries
Guidance notes for commissioners implementing the policy on Complex endovascular stent grafts in the management of abdominal aortic aneurysm
Guidance notes for commissioners implementing the policy on Complex endovascular stent grafts in the management of abdominal aortic aneurysm NHSCB/A04/P/a NHS England: Guidance notes for commissioners
Malignant Mesothelioma
Malignant Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)
New strategies in anticancer therapy
癌 症 診 療 指 引 簡 介 及 臨 床 應 用 New strategies in anticancer therapy 中 山 醫 學 大 學 附 設 醫 院 腫 瘤 內 科 蔡 明 宏 醫 師 2014/3/29 Anti-Cancer Therapy Surgical Treatment Radiotherapy Chemotherapy Target Therapy Supportive
Malignant Mesothelioma
Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)
CMScript. Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014
Background CMScript Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014 Prostate cancer is second only to lung cancer as the leading cause of cancer-related deaths in men. It is
Lung cancer forms in tissues of the lung, usually in the cells lining air passages.
Scan for mobile link. Lung Cancer Lung cancer usually forms in the tissue cells lining the air passages within the lungs. The two main types are small-cell lung cancer (usually found in cigarette smokers)
Clinical Practice Guidelines for Hepatocellular Carcinoma, List of Clinical Questions/Recommendations. Chapter. Grade. CQ No. 1 Interferon Therapy
Clinical Practice Guidelines for Hepatocellular Carcinoma, List of Clinical Questions/Recommendations Chapter Chapter 1 Prevention Sectio n CQ No. 1 Interferon Therapy Clinical Question 1 Does interferon
